These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17177896)

  • 1. Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists.
    Raitio KH; Savinainen JR; Nevalainen T; Järvinen T; Vepsäläinen J
    Chem Biol Drug Des; 2006 Dec; 68(6):334-40. PubMed ID: 17177896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
    Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
    J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
    Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
    J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
    Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
    Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.
    McLaughlin PJ; Qian L; Wood JT; Wisniecki A; Winston KM; Swezey LA; Ishiwari K; Betz AJ; Pandarinathan L; Xu W; Makriyannis A; Salamone JD
    Pharmacol Biochem Behav; 2006 Mar; 83(3):396-402. PubMed ID: 16616951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
    Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
    J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
    Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
    J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice.
    Ueda Y; Miyagawa N; Matsui T; Kaya T; Iwamura H
    Eur J Pharmacol; 2005 Sep; 520(1-3):164-71. PubMed ID: 16153638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
    Hou DR; Alam S; Kuan TC; Ramanathan M; Lin TP; Hung MS
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1022-5. PubMed ID: 19095444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.
    Lavey BJ; Kozlowski JA; Hipkin RW; Gonsiorek W; Lundell DJ; Piwinski JJ; Narula S; Lunn CA
    Bioorg Med Chem Lett; 2005 Feb; 15(3):783-6. PubMed ID: 15664857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
    Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
    Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
    J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
    Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
    J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
    Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
    Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
    Marriott KS; Huffman JW; Wiley JL; Martin BR
    Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
    El Bakali J; Muccioli GG; Renault N; Pradal D; Body-Malapel M; Djouina M; Hamtiaux L; Andrzejak V; Desreumaux P; Chavatte P; Lambert DM; Millet R
    J Med Chem; 2010 Nov; 53(22):7918-31. PubMed ID: 20979417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
    Montero C; Campillo NE; Goya P; Páez JA
    Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.